|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
139,126,000 |
Market
Cap: |
143.30(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.8871 - $4.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
17,438 |
35,533 |
57,514 |
116,582 |
Total Sell Value |
$26,639 |
$61,294 |
$139,194 |
$443,003 |
Total People Sold |
3 |
5 |
5 |
9 |
Total Sell Transactions |
3 |
9 |
12 |
23 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Leschly Nick |
President and CEO |
|
2018-01-05 |
4 |
S |
$173.26 |
$942,298 |
D/D |
(5,435) |
170,297 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2018-01-05 |
4 |
S |
$173.26 |
$530,530 |
D/D |
(3,060) |
24,245 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2018-01-05 |
4 |
S |
$173.26 |
$296,820 |
D/D |
(1,712) |
23,772 |
|
- |
|
Cole Jason |
Chief Legal Officer |
|
2018-01-05 |
4 |
S |
$173.26 |
$195,741 |
D/D |
(1,129) |
19,798 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2018-01-03 |
4 |
AS |
$180.10 |
$406,550 |
D/D |
(2,250) |
25,484 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2018-01-03 |
4 |
OE |
$50.51 |
$63,138 |
D/D |
1,250 |
27,734 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-01-03 |
4 |
AS |
$179.58 |
$1,081,781 |
D/D |
(6,000) |
15,977 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2018-01-03 |
4 |
OE |
$5.50 |
$33,002 |
D/D |
6,000 |
21,977 |
|
- |
|
Wentworth Kory James |
Principal Accounting Officer |
|
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
Leschly Nick |
President and CEO |
|
2017-12-13 |
4 |
AS |
$181.72 |
$21,629,119 |
D/D |
(117,500) |
175,732 |
|
- |
|
Leschly Nick |
President and CEO |
|
2017-12-13 |
4 |
OE |
$5.50 |
$208,317 |
D/D |
37,873 |
293,232 |
|
- |
|
Vachon Mark |
Director |
|
2017-12-11 |
4 |
AS |
$210.57 |
$1,516,465 |
D/D |
(7,000) |
1,000 |
|
- |
|
Vachon Mark |
Director |
|
2017-12-11 |
4 |
OE |
$30.47 |
$182,820 |
D/D |
6,000 |
8,000 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2017-12-11 |
4 |
AS |
$210.25 |
$2,143,785 |
D/D |
(9,900) |
27,305 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2017-12-11 |
4 |
OE |
$24.47 |
$242,253 |
D/D |
9,900 |
37,205 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2017-12-01 |
4 |
AS |
$171.81 |
$388,211 |
D/D |
(2,250) |
26,484 |
|
- |
|
Gregory Philip D |
Chief Scientific Officer |
|
2017-12-01 |
4 |
OE |
$50.51 |
$63,138 |
D/D |
1,250 |
28,734 |
|
- |
|
High Susanna Gatti |
Chief Operating Officer |
|
2017-12-01 |
4 |
S |
$172.15 |
$220,696 |
D/D |
(1,282) |
13,718 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2017-12-01 |
4 |
AS |
$171.72 |
$689,679 |
D/D |
(4,000) |
15,977 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2017-12-01 |
4 |
OE |
$5.50 |
$22,002 |
D/D |
4,000 |
19,977 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2017-11-10 |
4 |
AS |
$148.75 |
$1,480,865 |
D/D |
(9,900) |
27,305 |
|
- |
|
Walsh Jeffrey T. |
Chief Financialand Strategy Of |
|
2017-11-10 |
4 |
OE |
$2.09 |
$197,870 |
D/D |
9,900 |
37,205 |
|
- |
|
Leschly Nick |
President and CEO |
|
2017-11-01 |
4 |
AS |
$145.17 |
$308,779 |
D/D |
(2,127) |
255,359 |
|
- |
|
Leschly Nick |
President and CEO |
|
2017-11-01 |
4 |
OE |
$5.50 |
$11,699 |
D/D |
2,127 |
257,486 |
|
- |
|
Davidson David |
Chief Medical Officer |
|
2017-11-01 |
4 |
AS |
$144.44 |
$580,822 |
D/D |
(4,000) |
15,977 |
|
- |
|
864 Records found
|
|
Page 18 of 35 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|